# Innovative CRO Explorer

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovative-cro-explorer

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.ice-biosci.com
- Total disclosed funding: $28M
- Latest round: Series B (May 14, 2024)
- Investors on record: 13

## About

Founded in 2010 and based in Beijing, China, Innovative CRO Explorer is a biotech company that provides early drug discovery services from target validation to pre-clinical candidate identification. It has aboratories and business centers in Beijing, Shanghai, Xuzhou and Guiyang. The chairman of the board, Yan Li graduated from the University of Ruhr Bochum, Germany, and is a member of Daxing District CPPCC. In 2014, the company was funded by Beijing SME Innovation Fund. In 2021, it was certified as a national high-tech enterprise and Zhongguancun High-tech Enterprise. As of 2023, Innovative CRO Explorer has 7,000 square meters of laboratories and more than 350 employees. In May 2024, it closed a series B++ funding.

The company's main business is integrated biological services, target validation and development, target types and screening, protein degradation platform, drug efficacy evaluation, etc. It can provide more than 100 ion channels, 800 kinases/enzymes, 100 GPCRs, and 40 nuclear receptors assays on the shelf with validation data and screening information. The products are used in the fields of oncology, immunology, cardiovascular, and central nervous system diseases. It has developed target-based panel screening platforms that can accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection.

The company generates revenue by offering a full spectrum of drug discovery services, including target validation, lead optimization, and preclinical candidate selection.

The company will use the series B++ funding to support the provision of drug discovery biology research services to domestic and overseas pharmaceutical companies.

## Funding rounds

- Series B, May 14, 2024 — E-Town International Industrial Investment, Alwin Capital
- Series B, Aug 3, 2023, $14M — China International Capital Corporation, Addor Capital, Everest VC, Alwin Capital, Root
- Series B, Jan 19, 2023 — Root Venture Partners
- Series B, Sep 26, 2022, $14M — China International Capital Corporation, Lotus Lake Capital, Addor Capital, Jolmo Capital, Zhuhai Longmen Capital Management, Wuxi Guojing Investment Management, HIIG Equity Fund, Jifeng Ventures
- Series A, May 14, 2021 — Lotus Lake Capital, Jolmo Capital
- Angel, Apr 7, 2013 — Everest VC

## Investors

- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Angel, Series B
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A, Series B
- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A, Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series B
- Wuxi Guojing Investment Management (https://capitalatlas.ai/funds/wuxi-guojing-investment-management) — Series B
- HIIG Equity Fund (https://capitalatlas.ai/funds/hiig-equity-fund) — Series B
- Jifeng Ventures (https://capitalatlas.ai/funds/jifeng-ventures) — Series B
- Root Venture Partners (https://capitalatlas.ai/funds/root-venture-partners) — Series B
- Alwin Capital — Series B
- Root — Series B
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series B